Week 52:
- We wish all readers a happy and successful New Year!
- The oseltamivir SPC application from Gilead is formally reported
in the December 24th SPC...
- This week sees the first patent application from any major patent
office assigned to Microbiotix, a Massachusetts-based company
developing small molecule antiviral and antibacterial agents...
- Sertraline is now a target for Orion, the Finnish generics specialist,
as demonstrated in an application claiming a novel stereospecific
synthesis. Purity is clearly a major issue for Teva...
- UK Initial "A0" Applications filed November 14th - 21st 2002...
|
Week 51:
- Official PCT publication day for the next two weeks is Friday,
December 27th and January 3rd respectively...
- Delphion Research is the latest patent information vendor to
join Thomson Corporation...
- We referred to Wackvom here last week, specifically its fifth
neovascularization case, WO02098438, but then found this to be
a non-existent specification...
- Barry Potter, a medicinal chemist associated with Sterix Ltd,
received a mention here two weeks ago in the context of the mysterious
"Harry Potter" patent application from Paradigm Therapeutics
Ltd...
- Fordonal SA was the original assignee of EP134124, the patent
on which Almirall Prodesfarma based its SPC application for ebastine...
- Escitalopram is the subject of the latest application, SPC/GB02/049,
based on Lundbeck's EP347066 and a Swedish marketing approval
dated December 2001. If successful...
- UK Initial "A0" Applications filed November 8th - 14th 2002...
|
Week 50:
- One hundred thousand PCT applications have now appeared during
2002, the first year in which that milestone has been passed...
- Lilly will gain almost 2½ years' extra protection for the Xigris
sepsis treatment if its recent Supplementary Protection Certificate
(SPC) application in the UK succeeds...
- Celera, at the forefront of human genome research, virtually
never appears as applicant on patent documents; PE Corporation
is the usual name. There was recently an exception...
- Biofisica LLC has a Section F entry for the first time this
week, relating to wound healing electrotherapy...
- Wackvom Limited does not "Google", which is fairly
unusual for a company sufficiently sophisticated to file a coherent
series of PCT applications...
- Xzillion Proteomics GmbH has chosen a name suggestive of rather
large numbers, and that perfectly conveys the Frankfurt-based
company's specialism in the separation and characterization of
peptides and proteins...
- UK Initial "A0" Applications filed October 30th - November 7th
2002...
|
Week 49:
- Oseltamivir to get SPC protection, alfuzosin loses it...
- Having discontinued its Patent Express service, the British
Library is now once again promoting a remote patent document supply
service...
- Dr Stanley B Prusiner, recipient of a 1997 Nobel Laureate for
Physiology and Medicine, appears as inventor with colleagues from
the University of California, claiming advances in the field of
transmissible spongiform encephalopathies (TSEs)...
- More than a dozen applications from Pfizer see the light of
day this week, including a series of four on the use of adenosine
A2A agonists where there is involvement with Boehringer Ingelheim...
- Pfizer also has a new application bearing the title "Triazole
compounds useful in therapy"...
- UK Initial "A0" Applications filed October 23rd - 30th 2002...
|
Week 48:
- Another Supplementary Protection Certificate anomaly surfaces
this week with announcement that the US Government has been granted
SPC/GB99/039 with respect to reassortant rhesus/human rotavirus
serotype 1...
- From a new compound case in the joint names of Neurocrine Biosciences
Inc and SB Pharmco Puerto Rico Inc, it seems that the first patenting
is now beginning to emerge from a partnership first announced
in July 2001...
- Seven Indian inventions are among the new processes claimed
in this week's PCT applications, including three each from Aurobindo
Pharma and Ranbaxy...
- Coinciding with the announcement of collaboration between Pfizer
and Boehringer Ingelheim on the use of the German company's Spiriva
(tiotropium) in COPD...
- UK Initial "A0" Applications filed October 16th - 23rd 2002...
|
Week 47:
- A US application from Abbott was identified, relating to small
molecule purinoceptor modulators...
- More than 80 specialists in the patenting of pharmaceuticals
gathered in London this week for EuroLegal's conference entitled
Legal Strategies for Maximizing Pharmaceutical Patent Life Cycles...
- The grant of an SPC for NeXstar's DaunoXome (a liposomal formulation
of daunorubicin) was announced this week...
- Kannis is the name of a tribal community in the Indian state
of Kerala reported to have obtained the first patent for a tribal
medicine, according to the latest issue of Rouse & Co's MEISCA
ip express...
- UK Initial "A0" Applications filed October 10th - 16th 2002...
|
Week 46:
- AstraZeneca reveals novel pyridinone and related heterocyclic
derivatives...
- A US panel has advised the FDA to approve a new indication for
Novartis' antipsychotic drug Clozaril? If approved, this drug
will be used to prevent suicidal behavior in schizophrenic patients
who have failed other therapies...
- This Monday, Mylan and Genpharm announced regulatory approval
of their generic version of Roche's Accutane (isotretinoin). Protection
was lost under...
- A Danish court ruling in favour of Lundbeck this week prevents
Biochemie from selling a generic copy of the antidepressant citalopram...
- GSK continues to defend its rights to Augmentin in the US, adding
Lek (shortly to be acquired by Novartis) to the list of companies,
which are alleged to manufacture the drug using a stolen bacterial
strain...
- The list of possible therapeutic uses for PDE5 inhibitors increases
with Bayer's WO02089808 disclosure of their possible application
for improving cognition, concentration capacity, learning capacity
and/or memory retentiveness...
- Allied Domecq does not usually feature as an applicant in CP
Gazette, or even as a patent applicant at all, but it's first
PCT...
- UK Initial "A0" Applications filed October 3rd - 10th 2002...
|
Week 45:
- Wyeth continue a recent run of 5-HT1A antagonists with fourteen
PCT's for azaheterocyclylmethyl derivatives...
- UK Supplementary Protection Certificates (SPCs) have been granted
with respect to UFT (Taiho's EP500953), sibutramine (Boots' EP397831)
and sevelamer (GelTex's EP716606)...
- Novartis' SPC in respect of quinagolide, based on EP77754, entered
into force on October 6th...
- Patent expiry issues are closely watched by generic drug manufacturers
as they prepare to launch unbranded versions of successful pharmaceutical
products...
- Like indiplon referred to above, the dopamine/serotonin modulator
sarizotan is still at the clinical trials stage, but in this instance
the appearance of a synthesis case is entirely logical...
- Ardana Bioscience Ltd is seeking protection for a novel GnRH
modulator. A superficial search suggests that this is one of the
first patent applications from the Edinburgh-based company...
- UK Initial "A0" Applications filed September 26th - October
3rd 2002...
|
Week 44:
- Caspofungin, featured in a Merck process case last week (WO02083713),
has been granted a UK Supplementary Protection Certificate (SPC)...
- Coming into force on October 1st, Alcon's SPC for ophthalmic
irrigating solution, based on EP76658 is already half exhausted...
- Plavix (clopidogrel), the Sanofi-Synth?bo antithrombotic,
could begin to lose its basic patent protection within a few months...
- Alcon's olapatadine and AstraZeneca's ertapenem are the subject
of the two most recent applications recorded on the UK Patent
Office's SPC website...
- Further objections to Pfizer's erectile dysfunction use claims
for PDE inhibitors have meant that SIPO is considering an objection...
- UK Initial "A0" Applications filed September 18th - 26th 2002...
|
Week 43:
- Following the issue of US6469012 on 22 October 2002, Pfizer
has filed infringement lawsuits in the US District Court of Delaware
against GSK, Bayer, Eli Lilly, ICOS and the Lilly/ICOS...
- The contrast between legal decisions in US and Europe is further
illustrated in a case heard at the UK Court of Appeal relating
to omeprazole...
- Cefpodoxime is the target for generic drug companies from both
Korea and India this week, but whereas Hanmi is concerned with
the proxetil ester...
- Sibutramine is the subject, directly or otherwise, of two Sepracor
cases published this week. Our DOLPHIN database currently has
Associations linking 48...
- UK Initial "A0" Applications filed September 10th - 17th 2002...
|
Week 42:
- The European Patent Office (EPO) hosted its 12th Epidos Annual
Conference earlier this week in Copenhagen...
- Granted European patents this week include a case from Heidelberg
Pharma Holdings (HPH), a spin-off from that town's university...
- Friday 11th October finally saw the eagerly awaited announcement
of the judgment in AstraZeneca's long-running omeprazole dispute...
- Gene therapy developments have also been in the news this week.
A team of scientists at the Stanford University has revealed...
- UK Initial "A0" Applications filed September 5th - 10th 2002...
|
Week 41:
- US biotech firm Seattle Genetics announced on 8th October 2002
that its partner Genentech would no longer continue its involvement
in the development of SGN-14...
- On Thursday 26th September 2002, Impax Laboratories revealed
that Purdue Pharma has brought a suit against its generic form
of the analgesic, OxyContin (oxycodone)...
- Three SPC applications have appeared this week, the first (SPC/GB02/038)
from PhotoCure covers methyl aminolevulinate hydrochloride (Metvix)...
- Two UK priority applications for mutant protein and a refolding
method indicate a collaboration between GlaxoSmithKline Biologicals
and the University of Utrecht...
- UK Initial "A0" Applications filed August 28th - September 5th
2002...
|
Week 40:
- Sigma-Tau's five-year Supplementary Protection Certificate
(SPC) for valaciclovir, based on EP77460, has now entered into
force; GSK is a licensee...
- Generic drug companies and chemical manufacturers from around
the world gathered in Paris earlier this week for the huge CPhI
conference and exhibition...
- UK Initial "A0" Applications filed August 20 - 28th 2002...
|
Week 39:
- Three new UK applications surface this week on the Patent Offices's
SPC website...
- China Health Services Newsletter from Lehman Lee & Xu contains
information relating to drug approvals in China...
- UK Initial "A0" Applications filed August 14th - 21st 2002...
|
Week 38:
- Patents information specialists from South-East Asia gathered
in Singapore last week for the first EAPIC event...
- Asian drug companies have as usual also contributed to this
week's chemical process innovations...
- Two new UK SPCs were granted in the final week of August, another
came into force, and one finally expired...
- Pharma Pacific Pty, with new claims to an interferon-alpha induced
gene, has an established collaboration in this field with Coulter
Pharmaceutical Inc...
- UK Initial "A0" Applications filed August 8th - 14th 2002...
|
Week 37:
- GlaxoSmithKline has taken an unusual approach in its battle
to fend off generic copies of its antibiotic best-seller...
- The verdict in a Sacremento based trial relating to herceptin
was revealed on September 6th 2002, finding in favor of Genentech
over Chiron...
- In other legal news, XOMA and Biosite revealed on September
10th that the patent and licensing disputes between them have
been settled out of court...
- Trademark issues have been in the headlines this week, as Lilly
prepares to launch an impotence therapy to rival Pfizer's sildenafil
...
- UK Initial "A0" Applications filed July 30th - August 6th 2002...
|
Week 36:
- The notification this week of an application for a new UK Supplementary
Protection Certificate relating to valganciclovir is a bit of
a puzzle...
- Thankfully the circumstances surround the SPCs filed by AstraZeneca,
Pfizer and Roche at the end of August are somewhat more straightforward...
- September 3rd 2002 saw another turn in the complicated legal
wrangling surrounding erythropoietin (Epo)...
- UK Initial "A0" Applications filed 22nd - 29th July 2002...
|
Week 35:
- Last Friday, as the Gazette was going to press, a change in
the ownership of Current Patents was announced...
- Yeda R&D has applied for a UK SPC in relation to glatiramer
acetate (Copaxone)...
- Pemetrexed, Lilly's phase III dihydrofolate reductase inhibitor,
in trials as Alimta for solid tumors, is now claimed for its antiviral
action in HMCV...
- Gr??thal features prominently with four new inventions relating
to the further development of two established products...
- According to Drug Patents 2001, approximately 45% of patenting
in the pharma/biotech field originates from the US. That is precisely
the case also in this week's process chemistry patenting...
- UK Initial "A0" Applications filed July 16th - 23rd 2002...
|
Week 34:
- Lilly's nizatidine finally emerged from SPC protection at the
end of July, just as AstraZeneca's dopexamine began...
- The UK Patents & Designs Journal includes the usual batch of
aging defense-related inventions...
- UK Initial "A0" Applications filed July 10th - 16th 2002...
|
Week 33:
- The USPTO, under fire on the PIUG bulletin board for making
changes to Official Gazette availability...
- New SPC applications continue to languish in the UK, and it
seems that the total number filed during 2003 will not reach 40...
- Generic intent from Teva is clear in two applications...
- Chemical process cases this week include one from Mercian, which
may serve to flag up the actual candidate isocoumarin...
- One of the week's more colorful applicants is Dr Christian Steup
of Hofheim, seeking protection for a method of converting a cannabidiol
into dronabinol...
- UK Initial "A0" Applications filed July 2nd- 9th 2002...
- Recent Conflict Reports...August 14th saw DOR BioPharma announce...
|
Week 32:
- Rejection of an SPC application is a rare event, but that is
the fate reported this week for SPC/GB98/010, from which Lundbeck...
- MEISCA IP Express is the name of a new bulletin circulated by
Rouse & Co...
- Panama is mentioned this week for only the second time in this
Gazette, although our DOLPHIN database has 205 occurrences...
- This week saw Pfizer move to strengthen their position in the
cGMP PDEV market...
- UK Initial "A0" Applications filed June 22nd - July 1st 2002...
|
Week 31:
- Roche finally lost basic UK protection for the analgesic ketorolac
on July 10th...
- There are four PCT applications this week from a Biotech start-up
company, Evolva...
- Apotex may be developing a strategy for its iron chelators designed
to overcome a weakness in patent protection for deferiprone...
- UK Initial "A0" Applications filed June 17th - 24th 2002...
|
Week 30:
- Romifidine, the Boehringer Ingelheim antihypertensive, has finally
lost SPC protection...
- An EPO opposition hearing concluded on July 24th that the so
called "Edinburgh" patent (EP695351) could be maintained
in an amended form...
- The Nuffield Council on Bioethics duly launched its discussion
paper entitled The ethics of patenting DNA on July 23rd...
- Sequential licensing is a feature of a pair of chemical process
cases published this week in the name of Schering Corp...
- In this week's Section A there is a cluster of four cases entitled
"Inhibitors of cruzipain and other cysteine proteases"...
- UK Initial "A0" Applications filed June 11th - 17th 2002...
|
Week 29:
- Pfizer's intended purchase of Pharmacia, announced on July 15th,
will result in a combined patent portfolio second in size only
to that of GSK...
- Mid-2016 is the expiry date of three UK SPCs granted during
June, and a fourth expires in August 2014...
- Generic drugs also feature in several chemical process cases,
alongside more than the usual number of PCT applications...
- The larger companies are making some moves that are predictable,
but others less so. Warner-Lambert's need to synthesize atorvastatin...
- UK Initial "A0" Applications filed 1st - 10th June 2002...
|
Week 28:
- UK SPC applications were lodged in mid-June by Yissum R&D for
calcitriol and by SCRAS for lanreotide...
- Patenting DNA is constantly making headlines, and two issues
have arisen this week...
- UK Initial "A0" Applications filed May 28th - June 5th 2002...
|
Week 27:
- Miraculously, this week's PCT applications have been published
on time, numbered in the new 8-digit format...
- According to the UK Patent Office's SPC website, it is now almost
three months since an application was filed...
- The Indian Patent Act 1970 was modified by an Act passed on
May 14th implementing some of the changes required by TRIPS...
- Process cases this week from India and Germany read directly
onto established products, while others from Japan and Canada...
- UK Initial "A0" Applications filed May 22nd - 28th 2002...
|
Week 26:
- The official journal of the UK Patent Office announces this
week the granting of four new Supplementary Protection Certificates...
- GSK's work on GSK (glycogen synthase kinase) shows evidence
of further progress this week...
- Mystery seems to surround Pfizer's farnesyl protein transferase
inhibitor program...
- The Belgian company UCB goes back to a compound first synthesized
more than 40 years ago...
- Additional indications are also the concern of Wyeth, whose
claims to the use of retigabine focus on anxiety disorders, including
phobias...
- Bayer has an application to new uses of ramatroban, the TXA2/PGD2
antagonist...
- UK Initial "A0" Applications filed May 14th - 21st 2002...
|
Week 25:
- Bayer appears to be at the start of a new program with a PCT
application claiming a series of...
- A certain degree of confusion also surrounds the Supplementary
Protection status of Pharmacia's recombinant factor VIII...
- There were further announcements of SPC grants to Serono and
Stryker Corporation this week...
- UK Initial "A0" Applications filed May 9th - 14th 2002...
|
Week 24:
- On 10th June, Triangle Pharmaceuticals of North Carolina announced
what it believes to be the final settlement in one...
- Ortho Pharmaceuticals, Ligand and Aventis Pharm are among the
recipients of new Supplementary Protection Certificates...
- The UK priority applications of most interest this week would
seem to come, not from the big pharma giants but from smaller
research interests...
- UK Initial "A0" Applications filed May 1st - 8th 2002...
|
Week 23:
- MOLMED SpA appears as one such applicant on a pair of April
30th filings entitled "Conjugate"...
- Generic drug companies' plans and intentions are revealed in
several documents published for the first time this week...
- Wockhardt, though not named formally as applicant, may well
be behind an application relating to a formulation of cefuroxime
axetil...
- UK Initial "A0" Applications filed April 22nd - 29th 2002...
|
Week 22:
- Augmentin was the subject of a US Federal District Court ruling
against GlaxoSmithKline...
- Four UK SPC grants (one of them agrochemical), two entries into
force and one lapsing are reported this week but apparently no
new applications...
- The two SPCs entering into force relate to Aventis' (Hoechst's)
antibacterials cefpirome and cefquinome...
- UK Initial "A0" Applications filed April 16th-22nd 2002...
|
Week 21:
- Scotia Holdings plc has applied for a UK SPC for the photosensitizing
porphyrin derivative mTHPC...
- Italy (like France) introduced its own national SPC system ahead
of the EU system that came into effect in 1993...
- "Submarine" patents, so called because they can remain hidden
below the surface for a long time, are normally a feature only
of the US patent system, but...
- UK Initial "A0" Applications filed April 8th-16th 2002...
|
Week 20:
- PCT applications were also modest in numbers this week, but
in contrast we found almost 500 US Published PreGrant applications...
- Two Canadian applications on taxoid purification and extraction
serve to confirm the continuing importance...
- University spin-offs featured this week include ProImmune Ltd,
Bookham Technology plc, Morphotek Inc...
- Medeva's Hepacare recombinant antigen, covered by EP304578,
is the subject of a UK SPC...
- UK Initial "A0" Applications filed April 2nd - 8th 2002...
|
Week 19:
- Hassle's UK SPC for omeprazole, based on EP5129, finally expired...
- On May 3rd Azko announced that it has filed an infringement
suit against Barr Laboratories...
- Generic companies patenting process technology include the Indian
companies Orchid (a cephalosporin intermediate) and Ranbaxy...
- AndRx has claims to sustained release formulations applicable
to such established products as Schering's loratadine and Merck-LIPHA's
metformin...
- UK Initial "A0" Applications filed March 25th - April 2nd 2002...
|
Week 18:
- The streets of London were disrupted on May 1st by May Day demonstrations,
but so too was the EPO's publication schedule...
- Earlier this week, Craig Venter revealed to his company Celera
Genomics that the human genome they recently sequenced...
- Leo Pharmaceuticals' sultamicillin Supplementary Protection
Certificate (SPC), based on...
- Research Disclosure is scanned each month for this Gazette,
nominally on the 10th, but in practice...
- Stimulating dendritic cells with LIGHT is the subject of one
of last week's PCT applications from SB...
- UK Initial "A0" Applications filed March 16th-22nd 2002...
|
Week 17:
- About 300 patent documentation professionals met earlier this
week in California, at the Annual Conference of the Patent Information
Users' Group (PIUG)...
- Roche has seen the patent position regarding its PCR technology
strengthened this week, announcing...
- Developments in the long-running omeprazole saga have seen AstraZeneca
receive two setbacks...
- Official notification of the grant of a Supplementary Protection
Certificate (SPC) to UCB for levocetirizine, optionally...
- UK Initial "A0" Applications filed March 7th - 15th 2002...
|
Week 16:
- SMi hosted its fifth annual event under the banner Supergenerics
& Patent Busting...
- Formal notice appears this week of the potentially controversial
levocetirizine SPC application filed by Sepracor...
- Merck has been thwarted in its attempt to obtain an extension
of its Australian patent covering the beta hydroxy metabolite
of lovastatin...
- Indications can be found among the new compound cases suggesting
that Gr??thal may be broadening its analgesic program...
- Substantial series of initial filings from Novartis, Glaxo and
AstraZeneca dominate the initial patent applications...
- UK Initial "A0" Applications filed February 28th - March 6th
2002...
|
Week 15:
- Nefazodone, the BMS antidepressant first approved in 1993, entered
its five-year Supplementary Protection Certificate...
- With the PIUG 2002 Annual Meeting fast approaching, it seems
appropriate to point out that US patent documents continue...
- The Swiss company ARS Holding NV (Applied Research Systems)
is especially difficult to track reliably...
- Sentec Ltd, Optinose AS, Meridica Ltd, Amura Ltd, Cambridge
Theranostics, DCA Design International...
- UK Initial "A0" Applications filed February 21st - 28th 2002...
|
Week 14:
- Generic manufacturer Watson Pharmaceuticals finally reached
a settlement with BMS...
- In other litigation news, Barr Laboratories and IMPAX have both
announced that they are challenging patents covering Aventis'
Allegra D...
- The issuance of four new UK SPCs has been announced this week...
- This week also saw the granting of EP907356, relating to the
AIR light particle pulmonary delivery system that Alkermes gained...
- Finally, among this week's new compounds can be found a pair
of cases from Prolifix, working in collaboration with...
- UK Initial "A0" Applications filed 14th - 21st Feb 2002...
|
Week 13:
- The Easter long weekend will have very little impact on availability
of the Gazette...
- In a bumper new compounds section this week, several cases can
be found that may read on to established products and development
programs...
- Cancer is also the target of Abbott's entry in Section A. Specifically,
the focus is...
- Swiss based Actelion has claims to a series of arylalkane-sulfonamides
that act as endothelin receptor antagonists...
- UK Initial "A0" Applications filed 6th - 13th Feb 2002...
|
Week 12:
- Imatinib features twice this week, once in an SPC application
and once in a new compound case...
- Aventis is responsible for the second SPC application filed
during the first week of March 2002, relating to the Ondeva...
- Vertex is the applicant on a notable series of new compound
cases relating to protein kinase inhibitors...
- GSK features in some rather unusual relationships, including
one with the mysteriously-named Golden Helix Inc...
- GW Pharma (no relation!) has filed an initial UK application
for the treatment of nausea...
- UK Initial "A0" Applications filed January 28th - February 6th
2002...
|
Week 11:
- The email version of the Gazette now includes hyperlinks to
PatentOrder, a public patent server-based document delivery service
using proprietary software from Minesoft Ltd...
- Patent Information is the title of a one-day course listed by
Management Forum...
- Formal notice is given this week by the UK Patent Office of
an application from Almirall Prodesfarma...
- Raga Consultores, based in northern Spain near Valladolid, is
a relatively new arrival on the generic drug scene...
- A cluster of more than a dozen US PCT applications relating
to proteins...
- UK Initial "A0" Applications filed 22nd-30th January 2002...
|
Week 10:
- ICN's antiviral ribavirin is the subject of an SPC application
in the UK...
- Generic drugs feature strongly in this week's Section C, covering
new process technology...
- Another Sanofi-Synth?bo link is implied by RPG Life Sciences'
claim to a one-pot synthesis...
- The Dr Reddy's application also serves to highlight a confusing
situation, in that in relates to a product which is the subject
of pending litigation...
- Sexual dysfunction is the theme of several cases involving BASF
and Pfizer...
- Ionix Pharmaceuticals Ltd of Cambridge, UK, issued a press release
on March 5th relating to an agreement with Xenome Ltd...
- UK Initial "A0" Applications filed January 15th - 22nd 2002...
|
Week 09:
- Global Generic Pharmaceuticals - Yesterday, Today, Tomorrow
is the eye-catching title of a book recently published...
- No new UK SPC data have emerged this week, although we note
that UCB's SPC for levocetirizine should...
- UK Initial "A0" Applications filed January 9th - 15th 2002...
|
Week 08:
- The triple vaccine MMR has been the subject of much controversy
in the UK...
- Ciprofloxacin lost basic patent protection in the UK on January
29th 2002 when Bayer's SPC...
- Among recent SPC applications, the General Hospital Corporation
is seeking extended protection for its INOmax nitric oxide...
- Initial applications to the UK Patent Office during the first
week of January were sparse...
|
Week 07:
- A complicated, ongoing litigation between GlaxoSmithKline and
Genentech was back in the news...
- A similar storm appears to be brewing around GSK's co-filed
EP481791...
- Mifepristone, the controversial "abortion pill", is the subject
of a UK SPC that came into force on January 8th...
- UK Initial "A0" Applications filed 20th December 2001- 2nd January
2002...
|
Week 06:
- Patents were national headline news in the UK on February 7th
for rather the wrong reasons...
- Euphemisms for addiction seem to be in vogue...
- Hispanics with little or no patenting history feature twice
in this week's chemical process Section...
- GlaxoSmithKline, in various guises, contributed 50 new UK patent
applications during the ten-day period...
- UK Initial "A0" Applications filed December 13th - 22nd 2001...
|
Week 05:
- Pharmacia finally lost protection for cabergoline...
- Teva Pharmaceutical Industries Ltd of Israel is reported to
be preparing an imminent US launch of fluoxetine...
- Applied Genomics Inc of California has what seems to be a substantial
new collaboration with Stanford University involving breast cancer
genes...
- It is quite rare to encounter a Japanese innovator applying
for international patent protection...
- Reanimatology is a subject not unknown in the patent literature,
but most of the occurrences to date originate from Russia...
- UK Initial "A0" Applications filed December 7th-13th 2001...
|
Week 04:
- A further nail was driven into the coffin of a key Pfizer patent
covering sildenafil when the UK Court of Appeal...
- European patents granted this week include Merck Frosst's EP904269B,
with claims to dihydrofuran prodrugs of COX-2 inhibitors...
- The Whitehead Institute for Biomedical Research's EP700445B
has also been granted...
- December 2001 seemed at the time a quiet month in terms of UK
SPC activity, but it is now clear that six of the first seven...
- UK Initial "A0" Applications filed November 29th -December 7th
2001...
|
Week 03:
- After going to press with last week, we received news of a decision
in a long running license dispute between Roche and IGEN International
Inc...
- Cabinet Alice de PASTORS has issued a very helpful "SPC News"...
- American Home Products has a noteworthy sequence of applications
relating to combinations of estrogenic agents...
- Two generic companies, one a multinational's subsidiary, have
process cases published relating to products...
- UK Initial "A0" Applications filed November 21st - 27th 2001...
|
Week 02:
- Terbinafine, the Sandoz 1980s antifungal which is now reaching
the end of its basic patent life, is the focus of process development...
- Terbinafine and clarithromycin are the subject of European patents
applied for in August 1980 and May 1981 respectively...
- Speedel Pharma AG of Switzerland provides more intrigue, with
two cases relating to phenylpropanols and related propionic acids...
- UK Initial "A0" Applications filed November 15th-21st 2001...
|
Week 01:
- Relief, followed by concern, was our reaction on seeing that
the 2002 PCT number format still has only five serial digits...
- Possibly the final UK SPC applications for 2001 were lodged
at around the beginning of December...
- The UK Patent Office received 1249 applications for patents
between October 31st and November 14th 2001...
- The UK Registered Designs Act 1949 has recently been amended
in such a way as to bring UK law into line with those of other
countries...
- UK Initial "A0" Applications filed October 31st - November 14th
2001...
|
